L Zhang1, Y Pang, X Yu, Y Wang, M Gao, H Huang, Y Zhao. 1. Tuberculosis Department, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, No. 97, Machang, Tongzhou District, Beijing, 101149, People's Republic of China.
Abstract
PURPOSE: To investigate the linezolid (LZD) treatment outcome and correlation between in vitro susceptibility to LZD and clinical outcome. METHODS: We retrospectively reviewed records of tuberculosis (TB) patients who received treatment with linezolid between March 2012 and February 2013. RESULTS: A total of 43 extensively drug-resistant (XDR) TB patients identified by drug susceptibility testing were enrolled in this study, including 15 (34.9 %) received LZD as part of individualized treatment regimens. Among the 43 XDR TB patients, 15 patients (34.9 %) obtained favorable clinical outcome, including 9 (60.0 %) from LZD group and 6 (21.4 %) from control group without LZD. Statistical analysis revealed that the percentage of favorable outcomes of LZD group was significantly higher than that of control group (P = 0.011). Furthermore, we analyzed the LZD minimum inhibitory concentrations of Mycobacterium tuberculosis (MTB) isolates from patients in LZD group and identified 4 (26.7 %) resistant to LZD. All of the patients with LZD resistance harbored adverse clinical outcome, while most of the patients infected with LZD sensitive MTB harbored favorable clinical outcome (81.8 %, 9/11). Statistical analysis revealed that the percentage of favorable outcome among the patients with LZD resistance was statistically lower than that among the LZD susceptible group (P = 0.011). CONCLUSION: This study demonstrates that linezolid has efficacy against XDR pulmonary TB patients, even in shorter duration of administration. The XDR TB patients infected with LZD-resistant isolates were more likely to obtain the adverse clinical outcome under the treatment of regimen containing LZD.
PURPOSE: To investigate the linezolid (LZD) treatment outcome and correlation between in vitro susceptibility to LZD and clinical outcome. METHODS: We retrospectively reviewed records of tuberculosis (TB) patients who received treatment with linezolid between March 2012 and February 2013. RESULTS: A total of 43 extensively drug-resistant (XDR) TB patients identified by drug susceptibility testing were enrolled in this study, including 15 (34.9 %) received LZD as part of individualized treatment regimens. Among the 43 XDR TB patients, 15 patients (34.9 %) obtained favorable clinical outcome, including 9 (60.0 %) from LZD group and 6 (21.4 %) from control group without LZD. Statistical analysis revealed that the percentage of favorable outcomes of LZD group was significantly higher than that of control group (P = 0.011). Furthermore, we analyzed the LZD minimum inhibitory concentrations of Mycobacterium tuberculosis (MTB) isolates from patients in LZD group and identified 4 (26.7 %) resistant to LZD. All of the patients with LZD resistance harbored adverse clinical outcome, while most of the patients infected with LZD sensitive MTB harbored favorable clinical outcome (81.8 %, 9/11). Statistical analysis revealed that the percentage of favorable outcome among the patients with LZD resistance was statistically lower than that among the LZD susceptible group (P = 0.011). CONCLUSION: This study demonstrates that linezolid has efficacy against XDR pulmonary TBpatients, even in shorter duration of administration. The XDR TB patients infected with LZD-resistant isolates were more likely to obtain the adverse clinical outcome under the treatment of regimen containing LZD.
Authors: Neel R Gandhi; Paul Nunn; Keertan Dheda; H Simon Schaaf; Matteo Zignol; Dick van Soolingen; Paul Jensen; Jaime Bayona Journal: Lancet Date: 2010-05-22 Impact factor: 79.321
Authors: Giovanni Sotgiu; Rosella Centis; Lia D'Ambrosio; Jan-William C Alffenaar; Holly A Anger; Jose A Caminero; Paolo Castiglia; Saverio De Lorenzo; Giovanni Ferrara; Won-Jung Koh; Giesela F Schecter; Tae S Shim; Rupak Singla; Alena Skrahina; Antonio Spanevello; Zarir F Udwadia; Miquel Villar; Elisabetta Zampogna; Jean-Pierre Zellweger; Alimuddin Zumla; Giovanni Battista Migliori Journal: Eur Respir J Date: 2012-04-10 Impact factor: 16.671
Authors: Reynaldo Dietze; David Jamil Hadad; Bryan McGee; Lucilia Pereira Dutra Molino; Ethel Leonor Noia Maciel; Charles A Peloquin; Denise F Johnson; Sara M Debanne; Kathleen Eisenach; W Henry Boom; Moises Palaci; John L Johnson Journal: Am J Respir Crit Care Med Date: 2008-09-11 Impact factor: 21.405
Authors: G B Migliori; C Lange; R Centis; G Sotgiu; R Mütterlein; H Hoffmann; K Kliiman; G De Iaco; F N Lauria; M D Richardson; A Spanevello; D M Cirillo Journal: Eur Respir J Date: 2008-06 Impact factor: 16.671
Authors: J N Bucher; M B Schoenberg; I Freytag; U Lange; S Hofmann-Thiel; M O Guba; J Werner; A Eder; G Schelling; M Stangl Journal: Infection Date: 2015-10-23 Impact factor: 3.553
Authors: Kristina M Bigelow; Amelia N Deitchman; Si-Yang Li; Kala Barnes-Boyle; Sandeep Tyagi; Heena Soni; Kelly E Dooley; Rada M Savic; Eric L Nuermberger Journal: J Infect Dis Date: 2021-06-04 Impact factor: 5.226